CONTINUEThis site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Find out more.
  1. Front Page
  2. News By Topic
  3. Pfizer, Allergan Proposed Merger May Be An 'Inversion'

Pfizer, Allergan Proposed Merger May Be An 'Inversion'

by Mike Godfrey, Tax-News.com, Washington

02 November 2015


Two of the world's largest pharmaceutical companies, US-based Pfizer Inc. and Ireland-based Allergan Plc, have disclosed they are in merger talks to form what could be the largest-ever US corporate tax inversion, with a probable value of more than USD100bn.

Inversion techniques are being used by some US multinationals to move their tax residences abroad – away from the high 35 percent US headline federal corporate tax rate – and to unlock their unrepatriated earnings held offshore.

In an announcement on October 29, Pfizer confirmed that it is now in preliminary friendly discussions with Allergan in relation to a potential merger, in which it may move its corporate headquarters from New York to Dublin.

This followed an official statement made by Allergan under Irish takeover rules in which it disclosed that it had been approached by Pfizer.

TAGS: tax | business | Ireland | mergers and acquisitions (M&A) | corporation tax | corporate headquarters | multinationals | transfer pricing | United States

To see today's news, click here.

 















Tax-News Reviews

Cyprus Review

A review and forecast of Cyprus's international business, legal and investment climate.

Visit Cyprus Review »

Malta Review

A review and forecast of Malta's international business, legal and investment climate.

Visit Malta Review »

Jersey Review

A review and forecast of Jersey's international business, legal and investment climate.

Visit Jersey Review »

Budget Review

A review of the latest budget news and government financial statements from around the world.

Visit Budget Review »



Stay Updated

Please enter your email address to join the Tax-News.com mailing list. View previous newsletters.

By subscribing to our newsletter service, you agree to our Terms and Conditions and Privacy Policy.


To manage your mailing list preferences, please click here »